Arabic Arabic English English French French German German
dark

Vascepa reduces ischemic events in heart attack patients, trial finds

Data presented at ESC Congress 2021 Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Novartis’ Kymriah fails to hit primary survival endpoint in late-stage trial

Next Post

Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma

Related Posts
Total
0
Share